OncoMatch/Clinical Trials/NCT04654338
2 Ablative RadioTherapy Treatments for Prostate Cancer
Is NCT04654338 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies non-drug interventions for prostate cancer.
Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects, less cost and improved system capacity without sacrificing excellent cancer control rates. By the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be superior to standard external beam radiation. While two HDR fractions appear to optimize patient convenience and outcomes while minimizing costs, we wanted to determine the tolerability of combining one MR-guided HDR treatment with one SABR treatment to further reduce HDR resource use while maintaining favourable treatment outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C (TNM)
Grade: grade group 1grade group 2 (ISUP)
Low risk disease: T1-T2c, grade group 1, PSA < 10 ng/ml or Favorable intermediate risk disease: One of T2c, grade group 2, or PSA 10-20 ng/ml
Prior therapy
Cannot have received: pelvic radiotherapy
Previous pelvic radiotherapy
Cannot have received: transurethral resection of prostate
previous transurethral resection of prostate
Cannot have received: prostatectomy
previous prostatectomy
Cannot have received: HIFU
previous HIFU
Cannot have received: androgen deprivation therapy
Exception: Use of 5-alpha-reductase inhibitors permitted
Use of androgen deprivation therapy. Use of 5-alpha-reductase inhibitors permitted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify